

# Lou Gehrig's Disease: Market Research Report

<https://marketpublishers.com/r/L1FDACB3879EN.html>

Date: April 2010

Pages: 258

Price: US\$ 3,450.00 (Single User License)

ID: L1FDACB3879EN

## Abstracts

This report analyzes the Global market for Lou Gehrig's Disease in US\$ Million.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 37 companies including many key and niche players such as Aeolus Pharmaceuticals, Inc., Amorfix Life Sciences Ltd., Avicena Group, Inc., Ceregene, Inc., CytRx Corporation, Genzyme Corporation, Isis Pharmaceuticals, Inc., Knopp Neurosciences, Maas Biolab, NeuroNova AB, Sygnis Pharma AG, Teva Pharmaceutical Industries Ltd., and Trophos SA.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW

Global Market Analysis  
Sanofi-Aventis – The Only Drug Maker for ALS  
Rilutek  
Prevalence and Incidence of ALS  
The United States  
Canada

**Table 1.** Mortality Rate of ALS in Canada – A Historic Review (includes corresponding Graph/Chart)

The United Kingdom  
New Zealand  
Australia

**Table 2.** Mortality Rate in Australia for Years 2005 through 2007 (includes corresponding Graph/Chart)

#### 2. AMYOTROPHIC LATERAL SCLEROSIS – AN INSIGHT

Major Types of ALS  
Etiology  
Exact Causes of ALS Still Unknown  
Major Milestones in ALS Treatment Arena

Diagnosis  
Symptoms of ALS  
Initial symptoms  
Emerging Symptoms  
Use of BiPAP, IPPV and Mechanical Respirators in ALS  
Measures to Deal with ALS Problems  
Treatment  
Symptomatic Treatment

### **3.POTENTIAL THERAPIES FOR ALS**

Neurotrophic Factors  
Insulin-like Growth Factor  
Vascular endothelial growth factor  
Sangamo BioSciences to Develop SB 509  
Smaller Molecules  
RNA Interference  
Stem Cells Offer New Hope  
Studies on Stem Cells  
LTC to Develop New Lou Gehrig's Disease Models  
Herbal Treatment  
Lithium: A potential Treatment for ALS  
Advancements in ALS Genetics  
Select Pipeline Drugs for ALS Under Clinical Trials (2009)

### **4.CLINICAL TRIALS AND RESEARCH STUDIES**

CytRx Initiates Phase 2/3 Clinical Trial for Arimoclomol  
New Treatment for ALS Patients  
KNS-760704 Receives Orphan Designation  
KNS-760704 Enters Phase 2 Study  
Maas Biolab SBIR Initiates Phase 2 for Cyclosporin  
Researchers Identify New Gene for ALS

### **5.RECENT INDUSTRY ACTIVITY**

Merck to Purchase Insmmed's Assets  
NeuroNova Signs Agreement with Genentech  
Insmmed Inks a Deal with IDIS to Organize NPPs for IPLEXTM

Teva to Extend Branded Products in Niche Specialty Diseases  
Asklepios and ALS TDI Develop Latest Therapeutic Delivery Alternatives for ALS Treatment  
Medicare Extends DME Coverage of HFCWO to Cure Neuromuscular Disorders  
Neuralstem and Hospital of Taiwan Collaborate for Development of Neural Stem Cell Therapies  
Life Technologies to Create Neurodegenerative Disease Models  
Medicare Extends the Coverage of HFCWO to Cure Neuromuscular Disorders  
Sygnis Obtains Orphan Drug Status for AX200 in Spinal Cord Injury Treatment  
Insmed Obtains Royalty-Free Global Rights for IPLEXTM  
Q Therapeutics Collaborates with Johns Hopkins Research Team  
Aldagen to Collaborate with UC Davis  
ALS TDI Collaborates with CSC  
ALS TDI and Allen Institute for Brain Science Enter into Agreement  
Amorfix Completes Research Partnership with Biogen Idec  
Isis Receives Orphan Drug Designation  
Prize4Life Endorses BrainStorm to Develop ALS Cure  
ALS TDI Selects Microbix to Manufacture Adenoviruses  
Maas BiolAB Receives SBIR Grant  
Neuralstem Collaborates with University of Michigan  
ALS TDI and MDA Collaborate

## **6.PLAYERS VENTURING THE ALS MARKET**

Aeolus Pharmaceuticals, Inc. (US)  
Amorfix Life Sciences Ltd. (Canada)  
Avicena Group, Inc. (US)  
Ceregene, Inc. (US)  
CytRx Corporation (US)  
Genzyme Corporation (US)  
Isis Pharmaceuticals, Inc. (US)  
Knopp Neurosciences (US)  
Maas Biolab (US)  
NeuroNova AB (Sweden)  
Sygnis Pharma AG (Germany)  
Teva Pharmaceutical Industries Ltd. (Israel)  
Trophos SA (France)

## **7.ASSOCIATIONS INVOLVED IN ALS RESEARCH**

Northeast Amyotrophic Lateral Sclerosis Consortium (US)  
Muscular Dystrophy Association (MDA)  
The ALS Association  
ALS Society of Canada  
ALS Therapy Development Institute  
Motor Neurone Disease Research Institute of Australia

## **8.GLOBAL MARKET PERSPECTIVE**

**Table 3.** World Recent Past, Current & Future Analysis for Lou Gehrig's Disease by Geographic Region – US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 4.** World 10-Year Perspective for Lou Gehrig's Disease by Geographic Region –Percentage Breakdown of Sales for US, and Rest of World Markets for Years 2006, 2009 & 2015

## **III. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 37 (including Divisions/Subsidiaries - 38)  
Region/CountryPlayers  
The United States  
Canada  
Europe  
France  
Germany  
The United Kingdom  
Rest of Europe  
Middle-East

## I would like to order

Product name: Lou Gehrig's Disease: Market Research Report

Product link: <https://marketpublishers.com/r/L1FDACB3879EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L1FDACB3879EN.html>